Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes
Ескіз недоступний
Дата
2019
Назва журналу
Номер ISSN
Назва тому
Видавець
Анотація
Liraglutide (L) is the analogue of human glucagon-like peptide 1 which stimulates
glucose-dependent insulin secretion and can modify the level of inflammatory biomarkers.
L can influence NF-kB inflammatory cascade, but the mechanisms of anti-inflammatory activities
of L remain to be determined. In animal models L influenced an activity of Sirtuin l(SIRTl).
Moreover, recent evidences strongly suggest that SIRT1 up-regulation may serve as a potent
therapeutic approach against development and progression of diabetic complications. The aim of this
study was to investigate L effects directed on the pro-inflammatory NF-kB pathway and expression of
SIRT1 in obese patients with type 2 diabetes mellitus (DM).
Опис
Ключові слова
glucagon-like peptide 1 (GLP-1), liraglutide; diabetes, obesity, NF-kB, SIRT1, mediators of inflammation
Бібліографічний опис
Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes / L. G. Savchenko, N. I. Digtiar, l. G. Selikhova [et al.] // ROM. J. INTERN. MED. – 2019. –T. 57, № 3. – P. 233–240.